Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785253 | 1.00 | DRD3 (0.40) | DRD3TRPM8SRD5A2ACHEALDH1A1 | |
| SCHEMBL803739 | 0.87 | ACHE (0.37) | DRD3TRPM8ACHEALDH1A1KMT2A | |
| SCHEMBL27920564 | 0.78 | TAS2R14 (0.40) | DRD3TRPM8SRD5A2ACHEALDH1A1 | |
| SCHEMBL785634 | 0.78 | DRD3 (0.39) | DRD3TRPM8SRD5A2ACHEALDH1A1 | |
| SCHEMBL803298 | 0.78 | DRD3 (0.39) | DRD3TRPM8SRD5A2ACHEALDH1A1 | |
| SCHEMBL27920561 | 0.78 | TAS2R14 (0.40) | DRD3TRPM8SRD5A2ACHEALDH1A1 | |
| SCHEMBL784544 | 0.77 | TRPM8 (0.43) | DRD3TRPM8SRD5A2ACHETBXA2R | |
| SCHEMBL785923 | 0.77 | TRPM8 (0.43) | DRD3TRPM8SRD5A2ACHETBXA2R | |
| SCHEMBL785968 | 0.77 | TRPM8 (0.47) | DRD3TRPM8ALDH1A1 | |
| SCHEMBL785967 | 0.77 | TRPM8 (0.47) | DRD3TRPM8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | DRD3 85/4885TRPM8 180/4885SRD5A2 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.